First-trimester plasma asprosin and its association with gestational diabetes mellitus: A prospective cohort study
This prospective cohort enrolled 302 low-risk singleton pregnancies at 10–14 weeks, measured plasma asprosin, and assessed gestational diabetes at 24–28 weeks. Ninety-eight participants (32.5%) developed GDM. Asprosin varied with BMI but did not discriminate later GDM, with an AUC of 0.516. The study provides a first-trimester reference range and evidence against using this biomarker alone for early screening.